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Although prothrombin is one of the most widely studied enzymes in biology, the role of the thrombin A-chain has been neglected
incomparisontotheotherdomains.ThispapersummarizesthecurrentdataontheprothrombincatalyticdomainA-chainregion
and the subsequent thrombin A-chain. Attention is given to biochemical characterization of naturally occurring prothrombin A-
chain mutations and alanine scanning mutants in this region. While originally considered to be simply an activation remnant with
little physiologic function, the thrombin A-chain is now thought to play a role as an allosteric eﬀector in enzymatic reactions and
may also be a structural scaﬀold to stabilize the protease domain.
1. Biosynthesis of Prothrombin
Prothrombin is a single chain glycoprotein of Mr 72,000 that
circulates in plasma at a concentration of 100–200μg/mL.
As shown in Figure 1, prothrombin consists of four struc-
tural domains: the Gla domain, a region containing 10
γ-carboxylated glutamic acid residues which mediate pro
thrombin binding to procoagulant phospholipid surfaces;
two kringle domains, which are thought to be involved
in protein-protein interactions; and lastly the trypsin-like
serine protease domain, which contains the enzyme active
site. Disulﬁde bonds and cleavage sites are also shown in
Figure 1. Prothrombin also has three N-linked carbohydrate
chains at residues Asn78, Asn100 (located in the kringle
domain 1), and Asn373 (present in the serine protease
domain) [1].
Prothrombin is synthesized in the liver as a precursor
containing an N-terminal pre-propeptide of 43 amino
acids. The presequence, or signal peptide, functions in the
cotranslationaltransferoftheproteinacrosstheendoplasmic
reticulum membrane and is removed by signal peptidase.
The propeptide comprises in part the recognition sequence
for a vitamin K-dependent carboxylase that converts the
10 glutamic acid residues in the Gla domain (at the N-
terminal region of prothrombin) to γ-carboxyglutamic acid
or Gla. These modiﬁed residues bind calcium (Ca++) leading
to a conformational change that is essential for assembly
of the substrate, prothrombin, with prothrombinase on
a procoagulant phospholipid membrane for subsequent
activation to thrombin. Following γ-carboxylation, the
propeptide is removed by enzymatic cleavage C-terminal
to an Arg-Arg sequence generating the new N-terminus
of the mature zymogen [1]. The ﬁnal posttranslational
modiﬁcation undergone by prothrombin prior to secretion
into the bloodstream is addition of the three N-linked
carbohydrate moieties.
2. Conversion to Thrombin
When coagulation is initiated at a site of vascular injury,
prothrombin is converted to thrombin by prothrombinase
(see [2] for a review of the cell-based model of coagulation).
As shown in Figure 1, factor Xa cleaves two peptide bonds in
prothrombin, initially cleaving at the Arg320-Ile321 bond to
generatemeizothrombin.Thisintermediateisthencleavedat
the Arg271-Thr272 bond to release fragment 1.2, consisting2 Thrombosis
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Figure 1: Activation of thrombin by the prothrombinase complex (reviewed in [4]). Prothrombin is colored by domain in this schematic,
highlighting the A-chain (pink) and B-chain (yellow). The gamma carboxylated Gla residues are noted by (Y) at the N terminus of
prothrombin, the carbohydrate attachment sites in kringle 1 (K1) and the B domain are noted by the shaded star, and the disulﬁde bridges
are shown. Factor Xa initially cleaves Prothrombin (a) at Arg 320 to produce meizothrombin (d), followed by cleavage at Arg 271 to
release fragment 1.2 from nascent thrombin (e). Thrombin then undergoes intermolecular autolysis to cleave the Arg 285/Thr 286 bond
(f), liberating the A13 peptide (pale pink) to generate α-thrombin. Experimental constructs used in biochemical studies of the thrombin
A-chain include prethrombin-1, which lacks fragment 1 (b) and prethrombin-2 (c).
of the Gla domain and the two kringle domains. Depending
on the order of peptide bond cleavage and in the absence
of a phospholipid membrane, an alternative intermediate
product called prethrombin-2 can also be generated over
the course of prothrombin activation [3]. The proteolytically
active thrombin molecule is comprised of a 49-amino acid
light chain (A-chain) linked by a single disulphide bond to
the 259-residue heavy chain (B-chain), which contains three
intrachain disulphide bonds. The serine protease domain
of thrombin is located in the B-chain. Nascent human
thrombin undergoes autoproteolysis at Arg284-Thr285 of
the A-chain, releasing a 13-residue N-terminal peptide and
yielding a 36-residue A-chain to form α-thrombin [4, 5]. It is
not currently known whether full A-chain nascent thrombin,
truncated A-chain α-thrombin, or both forms of thrombin
are present when coagulation is initiated in vivo or in plasma
[1].
3.Thrombin A-Chain
As shown in Figure 2, the A-chain of thrombin extends
along the surface of the B-chain in a shallow curved groove,
arranged in a boomerang-like shape opposite the active site
[6]. X-ray crystallography structures of human thrombin
show that the A-chain hinges the two interacting six-
stranded beta barrels of the B-chain. The A-chain interacts
with the B-chain through a network of six buried salt bridges
and ionic interactions, and ten interchain H-bonds that
stabilize the orientation of the B domain barrels. The A-
chain is further stabilized through several intramolecular
polar and salt bridge interactions [7]. The central portion of
the A-chain is most rigid, due to the presence of strong salt
bridge interactions (Figure 2). The X-ray crystal structure of
thrombin also reveals that both termini of the A-chain are
disordered, raising the question: “How much of the A-chain
is required to maintain thrombin stability and activity?” The
C-terminal segment up to Tyr14j is an amphiphilic alpha-
helix forming one and a half turns, showing a high degree
of ﬂexibility as well [6]. The N-terminal sequence of the A-
chain up to residue Glu1c is characterized by weak electron
density and appears to have a high degree of conformational
ﬂexibility. This suggests that this sequence does not interact
strongly with other parts of the thrombin molecule and
may not contribute signiﬁcantly to the overall structural
stability of the enzyme. However, there have been no studies
conducted to exclude other biological functions.Thrombosis 3
Prethrombin-2 is one of two prothrombin activation
intermediates and the immediate zymogen precursor to
thrombin [4]. Prethrombin-2 is comprised of the B-chain
and the full 49-residue A-chain. Mutation of the catalytic
triad serine (Ser195) to alanine results in a thrombin that
cannot autoproteolyse the A13 peptide from the N-terminus
of the A-chain [8]. X-ray structures of Ser195Ala thrombin
reveal additional hydrogen bonding between the ﬁrst 13
residues of the A-chain, the mature A-chain, and the B-chain
(Figure 2)[ 8]. The covalent interaction between the A and
B-chains is a disulﬁde bridge through Cys1(93)-Cys122.
The A-chain is stabilized by the Asp1a(92)-Lys9(301) and
Arg14d(310)-Glu13(314) ion pairs and the ion quartet
Arg4(96)-Glu8(300)-Asp14(306)-Glu14c(309). The ionic
interactions include Glu8(300)-Lys202-Glu14c(309), Asp14
(306)-Arg137, Lys14a(307)-Glu23, and Glu14e(311)-Lys135
-Asn159-Tyr194a. Hydrophobic stacking interactions
include Tyr14j(316)-Pro204, and Phe1m(280)-Phe1l(281)-
Phe1g(286) in the A13 peptide of the A-chain.
4. Evolution
4.1. Prothrombin Evolution. Genetic analysis of the clotting
factor genes demonstrates that the clotting proteases of the
chymotrypsinogen superfamily have evolved as a result of
several gene duplications, exon shuﬄing, and intron sliding
events. Gene organization studies reveal that factors VII, IX,
andXarecloselyrelatedandhaveevolvedseparatelyfromthe
homologous genes for factor XII, tissue-type plasminogen
activator, and urokinase. Prothrombin has a unique exon
organization and is thought to be the ancestral gene in this
clotting factor family [9].
Analysis of prothrombin genes across seven vertebrate
species has established that the most conserved regions of
prothrombin are the propeptide region, Gla domain, and the
thrombin B-chain. The least conserved regions are the A-
chain region and the interconnecting regions between the
Gla and kringle domains [9]. There is 54% amino acid
identity for the B-chains of thrombin encoding the protease
domain while only 40% amino acid identity for the A-
chain residues [10]. When conservative substitutions were
accounted for, the thrombin B-chains were found to have
75% identity across nine vertebrate species while the A-chain
was found to have 42% sequence identity [11]. Sequence
alignment of the thrombin A-chain across 11 vertebrate
species is shown in Table 1 [12]. Of the ten thrombin A-
chain residues that interact with the B-chain, ﬁve residues
are completely conserved, three are partially conserved, and
Ser288 and Thr308 are not conserved (Table 1).
4.2. Serine Protease Clan PA Subfamily S1. The subfamily
S1A of clan PA encompasses serine proteases bearing the
chymotrypsinogen fold and includes proteases with diverse
extracellular functions from digestion (e.g., chymotrypsin,
trypsin, and proelastase) to complement-mediated immu-
nity (factor B, factor D, factor I, C1r/s, and C2), ﬁbrinolysis
(urokinase, tissue-type plasminogen activator, plasminogen,
kallikreins) to coagulation (factors VII, IX, X, XI, pro-
thrombin, PC, and PS), and apoptosis (granzymes) to bone
remodelling (osteocalcin) [13]. A detailed review of the
serine peptidase family and clan classiﬁcation system is
provided in [13].
While some homologous proteases such as trypsin lack
an A-chain altogether, other homologous clotting proteins
that remain tethered to phospholipid membranes, such as
factors Xa, IXa, APC, and VIIa retain the remainder of the
zymogen through a covalent disulﬁde bridge with Cys122 on
the B domain [14]. While it is not currently known whether
associated zymogen protein domains inﬂuence the protease
domain in any S1 peptidase, it is considered a plausible
scenario [14]. When present in other serine proteases
including urokinase and tissue plasminogen activator, a
noncatalyticA-chaindisulphidebondedtotheactiveB-chain
appears to have an allosteric eﬀect on the enzymatic activity
[15]. The noncatalytic light chains of plasmin and factor
XI also contain binding sites for physiological substrates
[16, 17]. Six residues of the prothrombin A-chain region
are homologous to the propeptide of chymotrypsinogen.
However, the chymotrypsinogen propeptide is not involved
in substrate or inhibitor binding [6] .Ar e c e n tN M Rs t u d y
has also revealed that in the absence of stabilizing ligands,
the protease domain regions of highest stability are ﬂanked
by the light chain of thrombin. The authors suggest that the
A-chain may play a ligand-like role to stabilize and maintain
the integrity of the protease domain in the absence of other
ligands [18].
4.3. Snake Venom Thrombin-Like Enzymes (SVTLEs). The
venoms of many snake genera contain serine proteases
that share approximately 26–33% sequence identity with
thrombin [19]. One class of these venom proteases is known
as thrombin-like due to their ability to cleave ﬁbrinogen to
release ﬁbrinopeptide A and/or B [20]. Other thrombin-like
activities are found in snake-derived proteases such as ceras-
tobin, batroxobin, ancrod, crotalase, Russel’s Viper Venom-
V, and thrombocytin, which activate platelets, ﬁbrinogen,
factor V, factor XIII, and protein C [20]. SVTLEs and throm-
binshareasimilarcatalyticmechanismandhaveaconserved
structure thought to have evolved from a common ancestral
protease [21]. As compared to thrombin’s three-intrachain
and one-interchain (A-B) disulﬁde bridge, SVTLEs contain
twelve cysteine residues, ten of which form disulﬁde bridges
based on homology with trypsin [22]. The remaining two
cysteines form a unique and highly conserved disulﬁde bond
in the C-terminal tail of SVTLEs. SVTLEs are either one- or
two-chain proteins synthesized as zymogens with proposed
activation peptides of six amino acid residues (Q-K-S-S-E-L)
[23]. However, none appear to have a light chain that bears
homology to thrombin [19]. Additionally, the conserved
Cys122 (chymotrypsin numbering) which forms the A-B
interchain disulﬁde of thrombin has been identiﬁed as a
serine residue in all known SVTLEs [19]. Previous studies
havesuggestedthattheaminoacidsequencesofvenomgland
serine proteases have diversiﬁed in an accelerated manner
















Figure 2: Pymol-generated structure of thrombin using the PDB 3GIS coordinates of Ser195Ala thrombin [8]. (a) Interactions between
the A-chain and the B-chain of thrombin (B-chain residues are labeled in blue, the 36-amino acid residue A-chain is colored in
green, and the covalently bound A13 peptide segment is colored magenta. The covalent disulﬁde bridge between the A- and B-
chains is through Cys1(93)-Cys122, as shown in orange. Hydrogen bonds are colored yellow and residue numbering is based on
chymotrypsinogen, with prothrombin numbering for the A-chain provided in brackets. The A-chain is stabilized by the Asp1a(92)-
Lys9(301) and Arg14d(310)-Glu13(314) ion pairs and the ion quartet Arg4(96)-Glu8(300)-Asp14(306)-Glu14c(309). The ionic interactions
include Glu8(300)-Lys202-Glu14c(309), Asp14(306)-Arg137, Lys14a(307)-Glu23, and Glu14e(311)-Lys135-Asn159-Tyr194a. Hydrophobic
stackinginteractionsincludeTyr14j(316)-Pro204andPhe1m(280)-Phe1l(281)-Phe1g(286)intheA13peptideoftheA-chain.(b)Thrombin
structure showing active site residues in red and location of the A-chain on the opposite face of the molecule.
Table 1:ProthrombinA-chainsequencealignmentacross11vertebratespecies.NCBICDDPfam09396[12].Inthethirdcolumn,conserved
residues are shown in regular font, and nonconserved residues are marked in italic font. 12 human prothrombin A-chain residues interact
with the B-chain and are shown underlined. Human prothrombin numbering is provided underneath the sequences.
Species Common name A-chain sequence
Homo sapiens Human TATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGR
Mus musculus Mouse TTDAEFHTFFNEKTFGLGEADCGLRPLFEKKSLKDTTEKELLDSYIDGR
Rattus norvegicus Norway rat TTDAEFHTFFDERTFGLGEADCGLRPLFEKKSLTDKTEKELLDSYIDGR
Bos Taurus Cow TSEDHFQPFFNEKTFGAGEADCGLRPLFEKKQVQDQTEKELFESYIEGR
Elaphe sp. Elephant TTIQQHETFFDPKTFGEGEADCGIRPLFEKKKISDSTENELLESYLQGR
Gallus gallus Chicken TIFQEFKTFFDEKTFGEGEADCGTRPLFEKKQITDQSEKELMDSYMGGR
Struthio camelus Ostrich TVLQEYKTFFDDKTFGSGEADCGIRPLFEKKKIKDKSEKELLESYIGSR
Crocodylus niloticus Nile crocodile TSIPEYKVFFDPKTFGSGEADCGIRPLFEKKNIADKTEKDLLESYIEGR
Danio rerio Zebra ﬁsh TTLDQRKAFFNPRSFGNGELDCGERPLFEKINKADKNEKELLMSYTGSR
Oncorhynchus mykiss Rainbow trout TLSGPRQSFFSPQSFGSGELVCRERPMFEKMSKKDGREQELIDSYQGGR
Tetraodon nigroviridis Puﬀer ﬁsh TTLSSRKQFFNPRTFGQGENDCGQRPLFEKISKKDAKEDELLESYREKR
Xenopus laevis African clawed frog TTTEEHQTFFDEKTFGSGEAVCGLRPLFEQKSVEDKGEKELMESYMQGR
Human prothrombin numbering: 272 282 292 302 312Thrombosis 5
phylogenetic lineage of serine proteases [19]. It is possible
that these enzymes diverged from the chymotrypsinogen
family prior to the emergence of the A-chain.
5. NaturallyOccurring Mutationsin
Human Prothrombin
Of the 50 inherited prothrombin deﬁciencies reported in
the literature, only seven involve mutations in the A-
chain. Documented missense mutations of human thrombin
include in-frame deletions of three nucleotides in exon 9
(7484/7489 del. GAA), resulting in omission of one of two
lysine residues (Lys301 or Lys302) [24, 25]. The deletion of
either Lys301 or Lys302 leads to the removal of a salt bridge
interaction between Lys301 and Asp292, which is thought to
stabilizethecentreoftheA-chain.Theauthorssuggestedthat
hypoprothrombinemia is caused by the incomplete folding
of the A-chain, which is then unable to stabilize the B-
chain structure. Two recent studies on the Lys301 deletion
prothrombin mutant have suggested that A-chain structure
aﬀectstheconformationandcatalyticpropertiesofthrombin
through long range allosteric eﬀects on the active site and
insertion loops [25, 26]. Interestingly, a recent crystal struc-
ture of thrombin complexed with sulfo-hirudin found that
Lys301 participates in a divalent metal binding site between
the heavy and light chains of thrombin [27]. The authors
hypothesized that this metal binding site contributes to the
stabilization of the light chain conformation and may mod-
ulate thrombin activity, oﬀering an alternative biochemical
explanation for the hemorrhagic diathesis seen in patients
with the Lys301 deletion prothrombin mutation [26].
Another patient was identiﬁed as a compound heterozy-
gote for two prothrombin A-chain missense mutations also
located in exon 9 (Glu300Lys and Glu309Lys) [28]. These
mutations were designated prothrombin Denver I and II,
respectively, and both of these Glu residues are conserved
throughout vertebrate species from ﬁsh to humans (Table 1).
Theauthorshypothesizedthatthesemutationsinterferewith
the autocatalytic cleavage of the A-chain or activation by
factor Xa; however, no conﬁrmatory activity studies have yet
been reported.
Prothrombin San Antonio is a missense mutation result-
ing in an A to G substitution at nucleotide 7543, resulting in
an Arg to His substitution at residue 320. The Arg320-Ile321
bond is one of two prothrombinase-mediated cleavage sites
that generate thrombin. Replacement of Arg with His at this
site prevents cleavage by factor Xa, forming a dysfunctional
molecule[29].Similarly,Akhavanetal.[30]discoveredanA-
chain missense mutation resulting from a G to A transition
at nucleotide 7312, resulting in the substitution of Arg271
for His. In plasma prothrombin, the Arg271-Thr272 bond
is cleaved by factor Xa to form thrombin. The alternative
Arg271 replacement by His prevents cleavage by factor Xa
at this site and results in the formation of meizothrombin,
which has normal amidolytic activity but little ﬁbrinogen
clotting activity compared with normal human α-thrombin
[31]. This observation supports a role for the fully formed
A-chain in substrate recognition.
Akhavan et al. [32] also discovered prothrombin Segovia,
a G-A mutation at nucleotide 7539 of exon 9 of the
prothrombin gene. This resulted in the substitution of
Gly319 by Arg. The authors proposed that the substitution,
which occurs near the site of factor Xa-mediated cleavage of
prothrombin (Arg320-Ile321), altered the conformation of
the protein making the cleavage site inaccessible to factor
Xa. Taken together, mutational analysis of these naturally
occurring A-chain variants suggests that the A-chain of
thrombin plays a functional role or roles in vivo.
6.Thrombin A-ChainBiochemistry
Initial modeling and structural studies of thrombin sug-
gested that the A-chain may contribute to the determination
of substrate speciﬁcity based largely on its proximity to the
active site [33–35]. Early work on plasma-derived bovine
thrombin, however, suggested that while the A-chain is
strongly associated with the B-chain through an array of
noncovalent interactions and a disulphide bond, it does not
appear to play a substantial role in the catalytic activity
of thrombin [36]. Disulphide reduction, removal of the A-
chain,andsubsequentrefoldingoftheB-chaindemonstrated
that the A-chain is not required for proper B-chain folding
and that intrachain interactions of the B-chain are suﬃcient
to yield an active enzyme upon refolding. This refolded B-
chain cleaved ﬁbrinogen, tosyl-L-arginine methyl ester, and
other small peptide substrates at similar rates as refolded
two-chain thrombin. These results lead the authors to
conclude that the A-chain does not signiﬁcantly contribute
to either the catalytic activity or substrate speciﬁcity of
thrombin. A similar study by Pirkle et al. [37] conﬁrmed that
isolated bovine thrombin B-chain cleaves ﬁbrinogen and is
also able to activate factor XIII as shown by the generation
of cross-linked ﬁbrin polymers during clotting assays. These
studies concluded that prothrombin activation may require
the A-chain; however, once mature thrombin is generated,
the A-chain is superﬂuous. This suggests that the A-chain is
an activation peptide only.
Removal of the A-chain of human thrombin by disul-
phide bond reduction has also been attempted [38]. Reduc-
tive unfolding resulted in sequential generation of two par-
tially reduced intermediates prior to conversion to the fully
reduced form. Partial loss of B-chain disulphide bonds prior
to reduction of the interchain disulphide link was observed,
leading to denaturation of the B-chain structure and loss
of activity. From this study, the authors concluded that
the A-chain may be required for structural stability of the
mature thrombin protein through noncovalent interactions,
and that the A-chain is required for normal functioning of
theactivesiteofthrombin.Theauthorsalsoconducteddisul-
phidescramblingexperiments,demonstratingthatthrombin
is one of the few proteins that contain disulphide bonds
formed between cysteines that occur consecutively in the
primary structure of the protein. This arrangement more
typically resembles extensively scrambled protein isomers
and was found to result in weak conformational stability as
the native protein is easily converted to disulphide scrambled6 Thrombosis
isomers at low denaturant concentrations [38]. The authors
proposed that this unique disulphide arrangement and
consequent conformational ﬂexibility may be crucial for the
multiple bioregulatory functions of thrombin.
A number of linkage studies have investigated the eﬀects
of salt, pH, and temperature on thrombin amidase activity,
highlighting not only the importance of both cation and
anion binding sites, but also the allosteric communication
between these sites and the active site of thrombin [39–
46]. In particular, substrate binding to the catalytic pocket
was found to be controlled by two ionizable groups while
the catalytic activity of thrombin was controlled by a more
complex linkage scheme involving three ionizable groups
[46]. The authors postulated that the two ionizable groups
that aﬀect both kcat and km were the active site histidine and
the B-chain amino terminus, as these residues play similar
roles in other serine proteases. The third ionizable group,
which aﬀects catalytic activity but not substrate binding, was
suggestedtobe part ofthe anionbinding exosite ofthrombin
[44,46].Whiletheseearlystudiesdidnotspeciﬁcallyidentify
the A-chain as an allosteric eﬀector of thrombin activity,
they did emphasize the biological importance of allostery in
thrombin function and served as the foundation for future
mutagenesis studies addressing potential long-range linkages
between the thrombin active site and the A-chain.
7. MutagenesisStudies
Prothrombin and prethrombin-2 mutagenesis and recom-
binant expression studies of A-chain residues have revealed
that at least some A-chain residues impart functional eﬀects
on thrombin activity. In an extensive mutagenesis study,
Tsiang et al. [47] functionally mapped surface exposed
residues of thrombin that were capable of participating in
H-bonds and electrostatic interactions. Charged and polar
residues were chosen for mutation as these were considered
most likely to participate in the binding of charged ligands.
Prothrombin A-chain residues Ser288, Glu290, Asp292,
Lys301, Lys302, Ser303, Lys307, Arg310, Glu311, Glu314,
and Asp318 were individually mutated to alanine, expressed
in COS7 cells, and the unpuriﬁed mutants were function-
ally analyzed for amidolytic activity, ﬁbrinogen clotting,
protein C activation, and inhibition by thrombin aptamer.
A triple mutant (Ser288Ala/Glu290Ala/Asp292Ala) had
signiﬁcantly enhanced amidolytic and ﬁbrinogen clotting
activity while a double mutant (Glu314Ala/Asp318Ala) had
reduced ﬁbrinogen clotting activity, but slightly enhanced
protein C activation. Conversely, the Lys307Ala mutant
possessed signiﬁcantly reduced amidolytic and clotting
a c t i v i t y ,a sw e l la sr e d u c e dp r o t e i nCa c t i v a t i o n .T h e s e
resultsdemonstratethatchargedA-chainresiduescontribute
in thrombin activity toward both pro- and anticoagulant
substrates.
More recently, a site-directed mutagenesis study was
performed on charged A-chain residues known to be
involved in inter- and intramolecular interactions [48].
Prethrombin-1 A-chain mutants were expressed in BHK
cells and puriﬁed prior to functional analysis. Of the
analyzedmutants,Glu300,Asp306,Glu309,andArg296were
each found to be functionally compromised in terms of
hydrolysis of the chromogenic substrate H-D-Phe-Pro-Arg-
p-nitroanilide (FPR), release of ﬁbrinopeptides A and B,
activation of protein C, and Protease Activated Receptor-1
cleavage (PAR1). In particular, the Arg296Ala mutant was
most severely compromised with a 65-fold reduction in
FPR hydrolysis. The concomitant reduction in cleavage of
ﬁbrinogen, PAR1, and protein C conﬁrmed the molecular
origin of active site perturbation more than 20 angstroms
from the active site. The Arg296 side chain is stabilized by
strong ionic contacts in the ion quartet Arg296-Glu300-
Asp306-Glu309 and also interacts with Trp29 and Trp207 in
the B-chain via van der Waals forces. Alanine substitution
of Arg296 abrogates the ionic interaction, weakening the ion
quartet and perturbation of the A-chain stability through
Arg296Ala substitution and is thought to propagate long-
range to the active site via Trp29 and Trp207.
Papconstantinou et al. [48] also used alanine scanning
mutagenesis to investigate the functional eﬀects of the
naturally occurring mutations prothrombins Denver I and II
(Glu300Lys and Glu309Lys), Segovia (Gly319Arg), and San
Antonio (Arg320His). Arg320His and Gly319Arg aﬀect the
factor Xa P1 and P2 recognition sites, respectively, and these
mutations have previously been attributed to perturbation
of the zymogen activation process. The bleeding diatheses
associated with Glu300Lys and Glu309Lys may result from
their interference with the autocatalytic cleavage of the
A-chain or factor Xa-mediated activation [28]. However,
considering that these two mutations occur in the central
region of the A-chain, it seems plausible that these mutations
disrupt the structural stabilization of the A- and B-chains
after thrombin activation. Alanine substitution of Glu300
and Glu301 was found to result in a reduction in ﬁbrinogen
cleavage and PAR1 activation. It is expected that the charge
reversal of the naturally occurring Glu300Lys and Glu309Lys
mutations is substantially more disruptive than the alanine
substitution conducted.
The naturally occurring prothrombin Lys301 deletion
has been most extensively studied of all A-chain muta-
tions. This mutation has been found to result in reduced
substrate turnover for Phe-Pip-Arg-p-nitroaniline, reduced
antithrombin-III and protein C interaction, less robust
platelet activation, and reduced sodium ion sensitivity. By
contrast, thrombin-thrombomodulin and thrombin-platelet
glycoprotein Ibα interactions were unaﬀected [25]. Further
structural characterization revealed decreased stability of
the Lys301 deletion mutant and a weakening in the A-B
interchain interactions, resulting in faster dissociation of the
A-chainupondisulﬁdescrambling[26].Moleculardynamics
simulation of the eﬀects of Lys301 deletion revealed geo-
metric distortion of the catalytic triad and alteration to the
aryl-binding site within the active site, resulting in substrate
restriction to the active site cleft. In particular, there were
changes to the S2 subsite (Trp60d loop) and transition of
Trp215 (S3 subsite). These changes collectively resulted in
reduced catalytic activity, conﬁrming that alterations in A-
chain residues have the potential to transmit long-range
allosteric eﬀects to the active site [26].Thrombosis 7
8.SignalingandDisease
Thrombin plays a role in many processes linked to cancer
including thrombosis, inﬂammation, and tissue repair and
remodeling (reviewed in [49]). Recent work by Ebert et
al. [50] has identiﬁed the thrombin A-chain as a potential
diagnostic tool for gastric cancer. Patients with dyspeptic
symptoms could be distinguished from those with gastric
cancer by comparing levels of circulating liberated A-chain
with both speciﬁcity and sensitivity of this marker found
to be 80%. The authors speculated that the decreased
circulating A-chain levels observed in cancer patient serum
samples correspond to higher concentrations of intact active
thrombin in the tumor microenvironment possibly due to
reduced local proteolytic degradation of thrombin. While
this does not imply a speciﬁc role for the thrombin A-chain
in the tumor environment, it does suggest that additional
proteolytic events occur to liberate the A-chain from the
localized thrombin molecule. Given that activation peptides
released from prothrombin and other coagulation proteins
have signaling eﬀects [51–53], it is possible that released A-
chain peptides may have a similar function. A recent study
investigated the ability of various thrombin fragments to act
ashostdefensepeptides[54].Whilenoantimicrobialoranti-
inﬂammatorycapabilities weredetected forA-chain peptides
examinedunderphysiologicalconditionsinthisstudy,future
research involving (pro) thrombin fragmentation by a wider
array of host, bacterial, and viral proteases may identify A-
chain peptides that function within the immune system,
further expanding the biological roles of thrombin.
9. Summary
In this paper, we have summarized the current literature
on the thrombin A-chain. While thrombin is well known
to be an allosterically-regulated protease, there is a relative
paucity of data addressing the contribution of the A-chain
to thrombin function. Early studies on bovine thrombin
concluded that the B-chain alone is an active serine pro-
tease, suggesting the A-chain is an activation peptide only.
However, subsequent mutagenesis studies with naturally
occurring A-chain mutations indicate that this polypeptide
chain is of structural and/or functional importance. Given
the wide array of substrates and cofactors with which throm-
bin interacts, the extent of the physiologic and pathologic
roles of the A-chain remains unclear. Mutational analysis
and structural studies oﬀer the most promising approach
to clarify the nature of A-chain function. Our laboratory is
focusing on the mutation of conserved thrombin A-chain
residues to analyze functional eﬀects. We also intend to
further characterize impaired mutants with crystallography
studies to clarify the physiological role of the thrombin A-
chain as an allosteric eﬀector and not simply an activation
remnant.
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